Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735603 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants
A Phase 1 study, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT02735603 is a Phase 1 study that has completed, run by Orexigen Therapeutics. The registered enrollment target is 84 participants.
The verdict
NCT02735603, a Phase 1 study, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential effect of naltrexone and bupropion extended-release combination on cardiac repolarization in healthy participants.
Interventions
- OTHER Placebo
- DRUG Moxifloxacin
- DRUG Naltrexone HCl/bupropion HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02735603
The ClinicalTrials.gov registry entry for NCT02735603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02735603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02735603 about?
NCT02735603 is a clinical study titled "Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants". The purpose of this study is to evaluate the potential effect of naltrexone and bupropion extended-release combination on cardiac repolarization in healthy participants.
What is the current status of trial NCT02735603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2016-04. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02735603?
The interventions under investigation include: Placebo (OTHER), Moxifloxacin (DRUG), Naltrexone HCl/bupropion HCl (DRUG).
Who is sponsoring clinical trial NCT02735603?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.